The trajectory of companies tied to Sildenafil's past presents a intricate investment picture . While the initial surge generated substantial profits , generic competition have significantly diminished sales . Investing in associated pharmaceutical firms now requires a discerning assessment of intellectual property rights , evolving medical shifts